Immunomedics is a clinical biopharmaceutical company specializing in the development of monoclonal antibody-based therapies for the targeted treatment of cancer and other serious diseases. Recently, the company’s antibody-drug conjugate (ADC) sacituzumab govitecanRead More…
Recently, Rakuten Aspyrian, a clinical stage biotechnology company, announced a total of $284 million in Series C funding round with its antibody-drug conjugates based on photoimmunotherapy, including $134 million jointly funded byRead More…
Breast cancer is the most common cancer and cause of death among women. About 20% of breast cancers are HER2-positive (IHC3+ or IHC2+/ISH+), and the remaining 80% are HER2-negative. HER2 is aRead More…
Recently, Sutro Biopharma announced that the US Food and Drug Administration (FDA) has granted STRO-001 the orphan drug qualification for the treatment of multiple myeloma (MM). STRO-001 is a potential first antibodyRead More…
October 03, 2018 – Seattle Genetics and Takeda recently announced the evaluation of antibody conjugates Adcetris (brentuximab vedotin) for the treatment of peripheral T-cell lymphoma (PTCL, also known as mature Phase IIIRead More…
Seattle Genetics and its partner, Astellas, have recently announced that the patients were selected for EV-201, the key phase II clinical trial of an experimental antibody-drug conjugate (ADC) called enfortumab vedotin. TheRead More…
On July 18, Immunopharmas, a leading biopharmaceutical company in the field of antibody-drug conjugates, announced that the Biologics License Application (BLA) of its sacituzumab govitecan for the treatment of metastatic triple-negative breastRead More…
Recently, Yuning Chen, Ph.D., from Creative Biolabs was exclusively interviewed by Angelo DePalma, a journalist from Biocompare, and shared his forward-looking and professional view on antibody-drug conjugates( ADCs). Antibody-drug conjugates (ADCs) are a new implementationRead More…
Tagworks Pharmaceuticals in the University of Nijmegen Medical Center has developed a new technology that targets tumor to deliver chemotherapy drugs in extreme cases. By controlling the “click release” of a chemotherapeuticRead More…
Still reeling from the failure of its lead breast cancer candidate glembatumumab vedotin last month, Celldex has culled another two pipeline projects and now says it will focus its R&D efforts mainlyRead More…